New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.
Jayne Hornung
Advertisement
Chief clinical officer, MMIT (Managed Markets Insight & Technology).
Articles by Jayne Hornung
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
3
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
4
Pharma Funding Roundup: Violet Therapeutics' $4.75 Million Seed Extension Financing, Full-Life Technologies Completes $150 Million Financing
5